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Summary.-Plasma and buffy-coat vitamin C were estimated in 158 samples from
139 lung-cancer patients, at all stages of the disease. Most samples showed hypo-
vitaminosis C inboth estimations: 64% had plasma, and25% buffy-coat values below
the thresholds for incipient clinical scurvy (0.3 mg% and 10 jg/108 cells respectively).
Levels were diet-dependent and could be increased by oral supplements. Levels were
low both in tumour-bearing patients and in those clinically free of disease after
resection. The latter had particularly low values during the first 6 months, indicating
the utilization of vitamin C in surgical repair.
The vitamin C content of 13 primary lung tumours was assayed: tumours had a
higher vitamin C content (mean 1116+551 ,ug/g tissue) than normal lung (58.5 +
20-4 ,ug/g).
Mononuclear cells from normal individuals show a higher vitamin C content than
polymorphs,butinlung-cancerpatientsthe expectedcorrelationofbuffy-coatvitamin
C with the proportion of lymphocytes in peripheral blood was obscured by an inverse
correlation in patients with relative lymphocytosis (.25% lymphocytes), confirmed
by an inverse correlation of the proportion of lymphocytes in peripheral blood with
mononuclear-cell vitamin C in 14 patients in whom this was measured. These
correlations were unaffected by controlling for plasma values, and indicate the
utilization of vitamin C in lymphocyte-related anti-tumour mechanisms.
Vitamin C is necessary for phagocytosis and for the expression of cell-mediated
immunity. In view of the increasing circumstantial evidence that immune mechan-
isms exert some measure of control on tumour extension and metastasis in man,
the effect of supplementation with vitamin C in lung-cancer patients on survival
should be tested in a clinical trial.
IN SPITE of the very poor prognosis of
lung-cancer patients (unless resection is
achieved before invasion of the nodes or
any other structures), there is now compel-
lingf circumstantial evidence that the
length of survival is influenced by defence
factors of an immunological nature. This
includes infiltration of the tumour by
mononuclear cells (Joachim et al., 1976; Di
Paola et al., 1977), eosinophils or macro-
phages (Kolb & Muller, 1979), reactivity of
the draining lymph nodes (Kaufmann et
al., 1977; Di Paola et al., 1977) and
peripheral lymphocytosis (Anthony et al.,
1981), which have all been shown to
indicate a better prognosis. In one study
(Di Paola et al., 1977) a host defence factor
derived from tumour infiltration and node
reactivity was more closely linked to
survival than the traditional assessments
ofthe malignancyofthetumour, makingit
unlikely that the associations described
were only secondary phenomena.
Recently vitamin C has been implicated
in the immune response. Several workers
have reported that high concentrations of
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the vitamin in vivo and in vitro increased
chemotaxis and lymphocyte blastogenesis,
both in normal individuals (Dallegri et al.,
1980; Manzella & Roberts, 1979) and in
patients with diseases characterized by
impaired immune reactivity (Anderson &
Dittrich, 1979, Rebora et al., 1980). Some
of the latter syndromes appeared to
respond to oral vitamin C (Anderson,
1981; Rebora et al., 1980).
Vitamin C depletion has been reported
to reduce some parameters of immune
competence (Thomas & Holt, 1978). Defi-
cient guinea-pigs showed delayed rejection
ofskin grafts (Kalden & Guthy, 1972) and
scorbutic guinea-pigs were unable to
mount a delayed-type skin reaction to
tuberculin after immunization (Zweiman
et al., 1966), though lymphocytes from the
same donors transferred reactivity to
normal animals. Reduced phagocytosis
accompanying steroid treatment was re-
versed by dietary supplementation with
vitamin C (Chretien & Garagusi, 1973).
None ofthe effects described necessarily
presuppose an essential effect on lympho-
cyte activity, but effects on both
polymorphonuclear and mononuclear
phagocytes have been clearly shown.
Vitamin C is rapidly depleted in acute
infections (Thomas & Holt, 1978) and in
the repair ofacute tissue damage (Hume et
al., 1972). Many of the chronic diseases
associated with low blood values for vita-
min C have an immunological component
(Thomas & Holt, 1978; Mullen & Wilson,
1976; Olusi et al., 1979).
InanumberofstudiesvitaminChasbeen
estimated in plasma and the buffy layer in
mixed groups ofcancer patients or in those
with advanced disease. Low values were
reported, particularly for buffy-coat vita-
min C (see Cameron et al., 1979). Two of
these studies included small numbers of
patients with lung cancer (7, Krasner &
Dymock, 1974; and 8, Kakar & Wilson,
1976). Low values in cancer have been
attributed to dietary insufficiency
(Krasner & Dymock, 1974) and to prefer-
ential accumulation of vitamin C in
tumours, since the vitamin C content of
tumour tissue exceeded that of surround-
ing normal tissue (Goth & Littman, 1948;
Kakar & Wilson, 1976). In the guinea-pig
(like man, unable to synthesize vitamin C)
vitamin C was necessary for tumour
growth; chemically induced tumours
showed regression on a scorbutic diet and
enhanced growth on a very high dose of
vitamin C (Migliozzi, 1977). In spite of
this, it has been suggested that mega-
dosage with vitamin C would be advan-
tageous in cancer patients (Cameron et al.,
1979). As far as we are aware, no estimate
of the vitamin C dosage necessary to
normalize vitamin C values in the blood of
cancer patients has been reported.
This paper examines the plasma and
buffy-coat vitamin C values of a large
series of lung-cancer patients at all stages
of the disease in relation to clinical state
and haeinatological values.
MATERIALS AND METHODS
Patients
One hundred and eighty-two blood samples
from 162 patients were examined (Table I).
Of these, 139 patients had primary bronchial
carcinoma, 60 tested during diagnosis, of
which 23 were subsequently resected (Stages
1-3). Of the 79 patients tested during follow-
up, 46 were considered free of disease after
resection when seen, and had no evidence of
recurrence at the time of analysis (9 months
to 2 years later). Twelve were judged to be
possibly recurring and 11 recurrent, taking
into account all information available at the
time of analysis. In 2 no allocation was pos-
sible. Six patients were tested during the
terminal phase, and 2 during follow-up after
exploration. In 121 of the 139 cases the
diagnosis was confirmed by histopathology.
The age range was 33-80 years, mean 63.
Twenty-eight samples were from women
(Table I).
In 20 patients, tested during diagnosis,
bronchial carcinoma was not found, though
in 3 it has not been finally excluded. Five
were found to have tumours of other sites or
metastases. Three other cancer patients were
tested after resection of tumours of the
cardia or oesophagus.
During the same period, the laboratory
undertook extensive studies of vitamin C
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TABLE I.-Diagnosis, clinical state and mean age ofpatients investigated
Diagnosis and state
Bronchial carcimona
On diagnosis
Later resected
Inoperable
Previously inoperable
Previously resected
Clear < 6 m p.o.
Clear 6 m to 20 yrs p.o.
Possibly recurring
Recurrent
State not known
Terminal
Other malignancies
Investigated controls
Total
Patients
Mean
No. age*
139 63
23
37
2
19
27
12
11
2
6
58
65
59
63
67
64
64
Number of samples (Women in parentheses)
Plasma and Complete
Total buffy-coatt datat
158 (26) 154 114 (15)
23 (1)
38 (6)
2
19 (8)
35 (8)
17 (2)
16 (1)
2
6
8 66 8 (2)
15 59 16
162 63 182 (28)
23
38
2
17
34
17
16
2
5
7
14
175
22 (1)
32 (5)
2
6 (3)
23 (4)
14 (2)
9
2
4
6 (1)
11
131 (16)
* No significant difference between control groups and lung-cancer patients (P>0.3):
significant variation among lung-cancer groups (P < 0.03) by analysis of variance.
t Three plasma and 5 buffy-coat values not done.
I Plasma and buffy layer vitamin C and differential.
levels in normal individuals, including those
in institutions and the elderly at home.
Blood samples
Blood samples were taken in the morning
without any precautions with regard to diet.
Blood for plasma and buffy-coat vitamin C
was drawn into heparin. Differential cell
counts (400 cells standard, 200 minimum)
were also performed on 139 samples (Table I)
and WBC counts on 110.
Preparation
Buffy-coat.-Two ml of heparinized blood
was mixed with 7 ml sedimenting fluid (25
parts 6% Dextran (mol. wt 15,000-20,000),
10 parts 0-9% saline and 1 part 10% EDTA),
transferred to another siliconized or plastic
tube and sedimented for 1 h (37°C). Seven ml
ofsupernate wasremoved andwellmixed, and
after removal of 100 /Ad for a cell count the
remainder was centrifuged (2000 g for 10 min)
and the supernate discarded. The pellet was
drained for a few seconds, the sides of the
tube dried and 0-6 ml of 5% TCA added and
vortex mixed with a fine glass rod. After
30 min at room temperature, the preparation
was frozen for at least 18 h.
Mononuclear cells.-Using the method of
B0yum (1968) mononuclear cells were pre-
pared by layering 3.5 ml blood diluted with
the same volume of saline, over Lymphoprep
(Nyegaard, Norway) and centrifuging for
40 min to give 400 g at the interface. The
interface cells were removed, washed x 3
with slow centrifugation to reduce platelet
contamination, suspended in 2 ml saline for
a cell count and then prepared as above.
Plasma.-One ml of plasma was added to
2 ml of 5% TCA, kept at room temperature
for 30 min and frozen as above.
Tumour preparation.-Samples of tumour
from 13 resections were chilled immediately
after resection, trimmed and cut into pieces
of 0-5 g, wrapped in foil in small plastic
tubes, frozen immediately andkept at -70°C.
On preparation, samples were thawed,
weighed, chopped and homogenized in a glass
homogenizer with 1-2 ml saline, vortex mixed
and allowed to stand for 1-i h. One ml was
decanted and added to 2 ml TCA. After
standing for 30 min, the preparations were
frozen for at least 18 h before assay.
Normal tissues
Thesamepreparativeprocedurewasapplied
to necropsy samples of human lung (6),
skeletal muscle (6) and brain (4).
Assay
Aliquots of0 5 ml ofthe supernatants from
TCA-precipitated plasma, buffy-coat. mono-
nuclear-cell or tissue preparations were
estimated for total vitamin C by the 2,4-dini-
trophenylhydrazine method as described by
Denson & Bowers (1961). Protein in the TCA
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precipitates of the tissue extracts was meas-
ured by the Lowry method.
Frozen preparations were kept at -30°C
for from 2 days to 2 months before assay.
Diet and dietary supplements
At the follow-up clinic, 37 patients were
interviewed about the drugs and dietary
supplements they were taking at that time,
about their smoking habits and about infec-
tions during the preceding month. Twenty-
seven patients were also asked whether they
ate fruit and green vegetables and how often.
Ifthey normally ate both fruit and vegetables
every day they were deemed to take a good
diet; either fruit or vegetables every day an
average diet, and neither regularly a poor
diet.
Analytic methods
Data was analysed using the SPSS pack-
age of computer programs (Nie et al., 1975).
Differences between groups were assessed
using the x2 test (or Fisher's Exact Test) or
the Kendall rank-order coefficient, -r. Correla-
tions were examined using the nonparametric
correlation programme to produce a matrix of
correlation coefficients (i-) which were exam-
ined for interactions using the partial correla-
tion programme. Matrices were produced for
the bronchial-carcinoma patients as a whole,
and for subgroups as follows: on diagnosis
later resected, inoperable at diagnosis, clear
after resection, recurrent etc. (previously
inoperable, recurrent and terminal); the
main subgroups were also examined for
patients with a squamous histopathology.
For examination of haematological para-
meters, separate matrices were produced,
including only the samples in which plasma
and buffy-coat vitamin C and differential
counts were all available.
Patients were grouped into those clinically
free of disease, those with resectable disease,
and those with inoperable, definitely recur-
rent or terminal disease, in order to study the
effect oftumourload. Tostudy "resectability"
patients at diagnosis were classified accord-
ing to whether resection was later achieved
or not.
Except where the direction of association
was expected from previous studies (e.g.
vitamin C levels with season, diet, age and
sex), P values quoted are 2-tailed.
The distribution of values for plasma and
buffy-coat vitamin C showed marked skew-
ness; nonparametric statistical methods were
therefore used.
RESULTS
Over several years this laboratory has
measured plasma and leucocyte vitamin C
in a number of population groups, many
concurrent with this survey oflung-cancer
patients. Values in these populations agree
well with the literature (Table II) and
allow us to establish tentative thresholds
below which plasma and leucocyte levels
are associated with scurvy and hypo-
vitaminosis C, a condition in which
reduced vitamin C reserves may affect
health though not leading to overt scurvy
(Basu & Schorah, 1982).
Plasma and buffy-coat vitamin C values
were low in bronchial-carcinoma patients
(Figs 1 and 2: medians, plasma 0-21 mg%,
buffy coat 13 ,tg/108 cells; means, plasma
0-31 mg%, buffy coat 159 ,ug/108 cells),
most patients having values below the
TABLE II.-Comparison of the mean vitamin C values in normal individuals and patients
with scurvy obtained in this laboratory with reports in the literature
Mean vitamin C values
< 55 years
> 65 years
Institutionalized
Scurvy
This laboratory
(numbers in parentheses) Literature
Buffy coat Plasma Buffy coat Plasma No. of
(,Ug/108 cells) (mg %) (qtg/108 cells) (mg %) studies*
31-4 (46) 1-03 (31) 29-1 0-88 7
25-6(88) 0-45 (102) 20-8 0 45 13
10-4 (142) 0-18 (246) 14-3 0-22 25
5-3 (5) 0.1 (5) 3-7 0 09 6
* Basu & Schorah (1982).
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FIG. 1. Plasma vitamin C by diagnosis and clinical condition at the time of testing.
Closed symbols-tumour-bearers.
threshold of hypovitaminosis C, and some
even below the threshold ofclinical scurvy
(Table III). Women showed rather higher
values than men (Table IV) but age
showed no clear effect on either the plasma
or buffy-coat vitamin C, except in the
patients clinically free of disease after
resection, amongst whom the tendency for
older patients to have lower plasma values
approached significance. In samples in
which a WBC count was also made, no
inverse correlation between the leucocyte
count and vitamin C in plasma or buffy
coat was found.
Seasonal fluctuations in both plasma
and buffy-coat values were found, tending
to be lower in spring and higher in late
summer of each year (Table IV).
Samples from 4 normal volunteers were
included among the patient samples; these
gave plasma values between 0-6 and
2-5 mg% and buffy-coat values between
33 and 78 tkg/108 cells. The investigated
controls showed rather low values for
vitamin C, but the median value for
plasma (0.28 mg%) was higher than that
in any of the lung-cancer subgroups, and
significantly higher than in the patients
tested during the 6 months after resection
(median 0 15, -r 0'30, P < 0.05).
Thirty-two of the previously resected
patients had been treated by pneumonec-
tomy and 19 by a less extensive operation.
There was a consistent tendency for
pneumonectomy patients to have lower
vitamin C values than those with less
extensive surgery, but it did not reach
significance.
Twenty-seven patients at the follow-up
clinic were asked about their consumption
of fruit and vegetables. Both plasma and
buffy-coat vitamin C tended to be higher
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TABLE III.-Number of samples from patients with bronchial carcinoma wvith vitamin C
levels below the thresholdfor hypovitaminosis C and scurvy
Hypovitaminosis C
Threshold Below
value No. (%)
Incipient clinical scurvy
Threshold Below
value No. (%)
Plasma vitamin C 0 35mg% 111 (70) 0-3m
in mg%
Buffy-coat vitamin C 18 tLg/108 103 (67) 10 ,Lg/l
tLg/108 cells
Both As above 95 (62) As abo'
in patients taking better diets (Table V),
significant among the group with recurrent
disease. Thirty-seven patients were ques-
tioned about other parameters. Ofthese, 3
were taking vitamin supplements, 8 were
current smokers (maximum 10 cigarettes/
day) and 12 had had recent infections. The
former tended to have vitamin C values in
the higher ranges, but neither smoking nor
infection was associated with lower vita-
min C values, compared to the group as a
whole.
The plasma and buffy-coat vitamin C
values for individual samples were closely
25
lg% 101 (64)
Frank clinical scurvy
Threshold Below
value No. (%)
0 1 mg% 30 (19)
Total
samples
158
39 (25) 8-6 /lg/108 27 (18) 154
36 (23) As above 16 (10) 154
related in the series as a whole (r 0 42,
P<0.001) and in most of the subgroups
(Table VI).
Although the vitamin C content of
normal mononuclear cells is 2-3 x that of
normal polymorphs (unpublished work),
the buffy-coat vitamin C values in lung
cancer patients were not significantly
related to the percentages of lymphocvtes,
monocytes or both (mononuclear cells) in
peripheral blood. There was a slight
tendency for higher buffy-coat vitamin C
values to be associated with higher
percentages of each variety of mono-
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TABLE IV.-The effect of sex, age and season on vitamin C values in lung cancer patients
Plasma
(mg%)
N Median P*
158 0*21
132 0-21
26 0-24
59
58
41
25
114
19
0-24
0-21
0-19
0-19
0*21
0 33
0-02
N.S.
0 03
Buffy-coat
(ug/108 cells)
, s A~~
N Median P
154 13-0
131 12 - 7
23 16-5
58
55
41
23
112
19
13 -4
12-9
12-8
10-8
13-1
18-2
0-02
N.S.
0-04
* By Kendall's rank-order correlation coefficient, L-tailed.
t Low-1 April to 16May; High-1 Aug. to 30Sept.; Mid-rest.
TABLE V.-The effect ofdiet onplasma and buffy-coat vitamin C in 27 samples from
lung cancerpatients duringfollow-up
Diet
Poor
Average
Good
P*
Lung cancer patients, after resection
Clinically clear Recurrent
Median vit C Median vit C
r
N Plasma Buffy-coat N Plasma Buffy-coat
(mg %) (,ug/108 cells) (mg %) (,ug/108 cells)
2 0-16 11-8 6 0-15 14-2
1 (0.02) (6.6) 8 0-19 15-2
6 0-52 15-0 4 0.55 20-0
N.S. N.S. < 0 005 <0.05
* By Kendall's rank-order correlation method.
TABLE VI.-Correlations between plasma and buffy-coat vitamin C and the proportion of
mononuclear cells in peripheral blood oflung cancer patients
Patients with bronchial carcinoma
'K
A
Number ofsamples
Correlationa of:
Plasma vitamin C with:
Buffy-coat vitamin C
% Lymphocytes
% Monocytes
Buffy-coat vitamin C with:
% Lymphocytes
% Monocytes
On diagnosis
All Later resected Inoperable
114 22 32
0.45*b 0.36**
0 07 0-17
0 09 014
0 lic
0-12d
0.13d
0 00
0-61*
0-01
0-08
0-13
0-17
"Clear" after
resection
29
Recurrent or
terminal
29
0.36* 0.33*
0-21 -0-01
-0 03 0-17
0 12e
0-08
0-10
0 33**f
a Kendall's rank-order correlation coefficient, T.
b For all 154 samples T=0-42, P < 0-001.
cLymphocytes <25% T= +0-16**, >25% r=-0-08n.s.
d Reduced by controlling for plasma vit C.
eLymphocytes <25% =+0-56**, >25% r=-0-38**.
f T = 0 29, P < 0-07 after controlling for plasma vit C.
*, **,P<0.01, <0*05.
All patients
By sex
M
F
By age (yr)
<60
60-69
70
By season
Lowt
Mid
High
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TABLE VII.-Assay of total vitamin C in
surgical specimens of 13 primary lung
tumours and in necropsy samples of
normal tissue
Vitamin C (mean and s.d.)
N jtg/g tissue pLg/mg protein
Primary lung
tumours
FLung
Normal Brain
LMuscle
13
6
4
6
111-6 + 55 - 1
58 - 5+ 20-4
110-7 + 25-5
14- 7+ 9-3
1-29+0-62
0-87+0-60
1 *38 + 0-48
0-22+0-12
patients clinically clear of disease after
resection (r= 0-32 P< 0-03).
Assay of vitamin C in 13 surgical
specimens of primary lung cancers gave
values double that for necropsy samples of
normal lung (Table VII). Values for lung,
brain and skeletal muscle were similar to
those reported in the literature (Basu &
Schorah, 1982). The same pattern was
evident when results were expressed as a
fraction of the weight of the tissue pre-
pared or of the protein content of the
homogenate.
Three terminal patients and a 4th
patient, in whom the diagnosis ofpulmon-
ary tuberculosis was made during the
study, were treated with vitamin C (1 g
daily x 3, 200 mg daily to 2 weeks); in each
case buffy-coat vitamin C rose during
treatment. Two patients received vitamin
C from the time of resection (1 g daily x 6,
300 mg daily to 3 months); plasma and
buffy-coat vitamin C values were in the
normal range when retested 6 weeks
and/or 6 months after resection (Table
VIII).
In this analysis involving the examina-
tion of 150 correlations, 2 would have been
expected to reach the 1% and 8 the 5%
level by chance alone. However, 7 correla-
tions reached the 0-1% level, 12 the 1%
and 27 the 5% level of significance (2-
tailed). The overall pattern of correlations
cannot have arisen by chance alone,
though individual correlations may have
done so.
DISCUSSION
Low values for buffy-coat vitamin C
have been reported previously in groups of
mixed cancer patients and those with
advanced disease; a few lung-cancer cases
were included. Krasner & Dymock (1974)
attributed the low levels primarily to
dietary deficiency; Kakar & Wilson (1976)
reported that tumour tissue (mainly skin
tumours) contained 3 times as much
vitamin C as surrounding normal tissue,
and postulated that low buffy-coat levels
were due to preferential accumulation of
vitamin C in the tumour.
Our study confirmed the low levels of
plasma and buffy-coat vitamin C in lung-
cancer patients in a much larger study,
including patients at all stages of the
disease, and underlines the complexity of
the factors determining the vitamin C
content ofplasma and leucocytes in cancer
TABLE VIII.-The effect of supplementation with vit C on plasma and buffy-coat vit C
values in 6 patients
Buffy-coat vit C
A
Pre-treatment
0-42
0-48
0-15
0-08
1 week 2 weeks
0-39 0 -72
0-24
0-17 0-75
Pre-treatment
12-9
10-1
8-2
11.9
Pt Pre-operative 2 weeks 6 weeks 6 months Pre-operative
5 0-13 0-51 0-61 16-9
6 0-21 0-99 0-70 18-7
1 week 2 weeks
21-6 22-0
12-4
20-2
20-8 38-0
2 weeks 6 weeks 6 months
27-5 29-4
32-5 45-0
Vitamin C regime: 1 g daily x 3 then 200 mg daily for 2 weeks (Patients 1-4), or 1 g daily x 6 then 300 mg
daily for 3 months (Patients 5 and 6). Patients 1-3 were suffering from terminal bronchial carcinoma; cases
5 and 6 from bonchial carcinoma, resected after the first sample; in case 4 the diagnosis ofpulmonary tuber-
culosis was made during study.
Plasma vit C
I A
Pt
1
2
3
4
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patients, pointing to additional important
factors.
Our findings support those ofKrasner &
Dymock (1974) in that buffy-coat vitamin
C levels in cancer patients were diet-
dependent. Seasonal differences were
noted throughout the study in agreement
with earlier findings from this laboratory
(Schorah et al., 1978) and, among inter-
viewed follow-up patients, on a crude
assessment, those who ate better diets
showed higher plasma and buffy-coat
vitamin C levels. In addition, the treat-
ment of terminal-cancer patients, and of
patients undergoing resection, with a
relatively modest regime of vitamin C
supplementation, increased both the
plasma and the buffy-coat vitamin C levels
in every patient (Table VIII).
However, there are reasons for suspect-
ing that dietary deficiency alone was not
responsible for the low vitamin C values
found, since levels were lower in post-
resection lung-cancer patients who were
symptom-free and had been so for months
to years, than in healthy controls in the
same area. Northern industrial towns are
known for poorer vitamin C intakes and
plasma concentrations (National Food
Survey Committee 1974; Exton-Smith,
1979). With barely adequate vitamin C
intake, even a mild increase in utilization
would deplete vitamin C reserves. In-
creased utilization could occur in several
ways in these lung-cancer patients.
Contrary to expectation (Pelletier,
1970; Hume & Weyers, 1973), there was
no evidence that either infections or
current smoking had contributed to the
low vitamin C values in lung-cancer
patients. Leucocyte counts did not cor-
relate inversely with vitamin C values, and
the latter were not lower in patients with
recent infections.
The higher vitamin C content of lung
tumour than of normal lung supports the
proposition ofKakar & Wilson (1976) that
increased accumulation ofvitamin C in the
tumour itself contributes to vitamin C
depletion. The apparent link between
poorly differentiated tumours (which tend
to grow faster) and low plasma vitamin C
in our data could also be construed in this
way, but may be spurious, since it was
strongest in the patients believed to be
tumour-free after resection.
Two other factors also seem to have
contributed: increased utilization of vita-
min C in repair after major surgery and
the chronic utilization in defence against
residual or recurrent disease. Vitamin C is
known to be used in the production of
connective tissue required in repair pro-
cesses (Tuderman et al., 1977; Nambisan &
Kurup, 1975). Accentuation of depletion
by major surgery would be expected
(Crandonetal., 1958; Shukla, 1969; Irwin
& Hutchings, 1976), and was demon-
strated in the vitamin C values recorded
for patients tested in the 6 months after
resection, and in the tendency for the
operation of pneumonectomy to be associ-
ated with lower levels during follow-up,
perhaps connected with the substantial
"repair" involved in organizing the clot in
the pneumonectomy space. What was
unexpected was that the levels remained
low for many years in the apparent
absence of recurrence.
Our data indicated that utilization of
vitamin C in tumour resistance also played
a part. Allowing for the contribution of
platelets to buffy-coat vitamin C, but not
substantially to mononuclear-cell vitamin
C, a proportionate increase in buffy-coat
vitamin C with increase in the proportion
of mononuclear cells in peripheral blood
would be expected, since normal mono-
nuclear cells contain 2-3 times as much
vitamin C as polymorphs (unpublished).
This was not seen in all the lung-
cancer patients but was seen in those
without lymphocytosis. In the patients
apparently free ofdisease after resection, a
direct relationship in patients with low
levels of lymphocytes turned into an
inverse relationship in those with relative
lymphocytosis. The dissociation occurred
at the upper end of the normal range for
lymphocytes, as cited by Wintrobe (1974),
and divided the patients into two groups
also differing in the likelihood of undetec-
364HYPOVITAMINOSIS C IN LUNG-CANCER PATIENTS
ted recurrent disease because oftheir very
different lengths of follow-up since resec-
tion. In neither group was the correlation
affected by controlling for plasma vitamin
C. This suggests that lower lymphocyte
counts and a direct correlation with buffy-
coat vitamin C reflected an "unreactive"
state, possibly because these patients had
no tumour to "react" to, and that their
plasma and buffy-coat vitamin C values
still showed evidence of incomplete recov-
ery after the depletion of the tumour-
bearing and postoperative repair phases.
There were echoes of this "unreactive"
pattern in patients with substantial tum-
our load, but in this case there were more
patients with extreme low values for both
lymphocyte counts and buffy-coat vitamin
C. Lymphocyte counts below the normal
range were always accompanied by low
buffy-coat and plasma vitamin C levels,
raising the possibility that nutrient defi-
ciency may contribute to the decrease in
circulating lymphocytes reported in
patients entering the terminal phase
(Chretien et al., 1973; Anthony et al.,
1975).
In contrast, patients with higher lym-
phocyte counts showed an inverse relation-
ship of lymphocyte count with the buffy-
coat vitamin C ("reactive" pattern), not
affected by controlling for plasma values;
lymphocytes contributing less to the
buffy-coat vitamin C with increasing
lymphocytosis. This is unlikely to have
been caused by inadequate intake alone
and is difficult to explain, unless vitamin C
is being used by some mechanism associ-
ated with the lymphocytosis. Lympho-
cytosis was first reported to be associated
with resistance to spontaneous tumours by
Murphy (1926) and has been linked to
longer survival ofinoperable patients with
squamous bronchial carcinoma, the cor-
relation being unaffected by controlling for
other factors (Anthony et al., 1981).
Significantly less vitamin C was present in
the mononuclear-cell fraction of present-
ing patients who were subsequently resec-
ted than in those of patients of poorer
prognosis, but there was less difference in
buffy-coat vitamin C. The better-prognosis
group also had higher lymphocyte counts.
This would be explained if utilization of
vitamin C by lymphocyte-related mechan-
isms in patients with some measure of
resistance to their tumours led to more
general cell and plasma depletion. Low
buffy-coat vitamin C has been reported in
conditions such as rheumatoid arthritis
(Mullen & Wilson, 1976) and asthma (Olusi
et al., 1979), in which chronic immune
reactions are involved. Evidence for the
utilization of vitamin C in the defence
against cancer has not previously been
presented.
Although the obvious conclusion to the
finding that vitamin C is utilized in
lymphocyte-relatedmechanismsinpatients
with lung cancer would be to assume that
vitamin C supplementation to maintain
normal buffy-coat vitamin C levels would
increase resistance to tumour extension,
this cannot be assumed, and our data
offers no evidence as to whether this would
be so. Regression of tumours in guinea-
pigs given only just enough vitamin C to
prevent death from scurvy, and enhanced
growth with very high vitamin C dosage
(Migliozzi, 1977), indicate that tumours,
like other tissues, require vitamin C for
growth. We have no evidence that vitamin
C depletion depressed the growth rate of
lung cancer in our patients; ifthis were so,
supplementation could also benefit the
tumour. On the other hand, vitamin C
depletion has been reported to interfere
both with effector capacity and with the
orchestration of the immune response. In
"reactive" patients with low vitamin C,
one would anticipate that supplement-
ation would allow fuller expression of cell-
mediated immunity and phagocytosis,
restoring some degree of tumour control
where this had been present; but in
"unreactive" tumour-bearing patients,
this would only be so if vitamin C
depletion were responsible for the state of
"unreactivity".
Our data are unable to predict the
overall effect of supplementation with
vitamin C, which could only satisfactorily
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be tested in the setting of a clinical trial.
Our results suggest, however, that rela-
tively modest dosage with vitamin C
would be adequate to prevent vitamin C
depletion, and that this level of dosage
would be worth testing.
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